WO2022053993A3 - Treatments for sars-cov-2 infection (covid-19) - Google Patents
Treatments for sars-cov-2 infection (covid-19) Download PDFInfo
- Publication number
- WO2022053993A3 WO2022053993A3 PCT/IB2021/058235 IB2021058235W WO2022053993A3 WO 2022053993 A3 WO2022053993 A3 WO 2022053993A3 IB 2021058235 W IB2021058235 W IB 2021058235W WO 2022053993 A3 WO2022053993 A3 WO 2022053993A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- covid
- cov
- sars
- infection
- treatments
- Prior art date
Links
- 208000025721 COVID-19 Diseases 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 2
- 208000037847 SARS-CoV-2-infection Diseases 0.000 title 1
- 239000013543 active substance Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Active agent combinations are provided for the treatment and/or prevention of COVID-19.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202041039535 | 2020-09-12 | ||
IN202041039535 | 2020-09-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2022053993A2 WO2022053993A2 (en) | 2022-03-17 |
WO2022053993A3 true WO2022053993A3 (en) | 2022-04-21 |
Family
ID=80631363
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2021/058235 WO2022053993A2 (en) | 2020-09-12 | 2021-09-10 | Treatments for sars-cov-2 infection (covid-19) |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022053993A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11655240B1 (en) | 2022-05-10 | 2023-05-23 | Beijing Grand Johamu Pharmaceutical Company, Ltd. | Crystal form of compound and fumaric acid, pharmaceutical composition and method for treating coronavirus-induced diseases |
CN117159556A (en) * | 2022-05-27 | 2023-12-05 | 北京远大九和药业有限公司 | Pharmaceutical composition and preparation method and application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004089383A1 (en) * | 2003-04-14 | 2004-10-21 | Cipla Limited | Pharmaceutical combinations comprising lamivudine, stavudine and efavirenz for treating viral infections |
US20150238489A1 (en) * | 2012-08-31 | 2015-08-27 | Novadrug, Llc | Heterocyclyl carboxamides for treating viral diseases |
US20200230198A1 (en) * | 2016-06-20 | 2020-07-23 | Kansas State University Research Foundation | Small molecule therapeutic inhibitors against picornaviruses, caliciviruses, and coronaviruses |
US20200276262A1 (en) * | 2017-10-06 | 2020-09-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Peptides for use in the treatment of viral infections |
-
2021
- 2021-09-10 WO PCT/IB2021/058235 patent/WO2022053993A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004089383A1 (en) * | 2003-04-14 | 2004-10-21 | Cipla Limited | Pharmaceutical combinations comprising lamivudine, stavudine and efavirenz for treating viral infections |
US20150238489A1 (en) * | 2012-08-31 | 2015-08-27 | Novadrug, Llc | Heterocyclyl carboxamides for treating viral diseases |
US20200230198A1 (en) * | 2016-06-20 | 2020-07-23 | Kansas State University Research Foundation | Small molecule therapeutic inhibitors against picornaviruses, caliciviruses, and coronaviruses |
US20200276262A1 (en) * | 2017-10-06 | 2020-09-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Peptides for use in the treatment of viral infections |
Non-Patent Citations (5)
Title |
---|
AMAT-SANTOS IGNACIO J.; SANTOS-MARTINEZ SANDRA; LóPEZ-OTERO DIEGO; NOMBELA-FRANCO LUIS; GUTIéRREZ-IBANES ENRIQUE; DEL VA: "Ramipril in High-Risk Patients With COVID-19", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 76, no. 3, 26 May 2020 (2020-05-26), AMSTERDAM, NL, pages 268 - 276, XP086213202, ISSN: 0735-1097, DOI: 10.1016/j.jacc.2020.05.040 * |
GAO YAN, YAN LIMING, HUANG YUCEN, LIU FENGJIANG, ZHAO YAO, CAO LIN, WANG TAO, SUN QIANQIAN, MING ZHENHUA, ZHANG LIANQI, GE JI, ZHE: "Structure of the RNA-dependent RNA polymerase from COVID-19 virus", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 368, no. 6492, 15 May 2020 (2020-05-15), US , pages 779 - 782, XP055934767, ISSN: 0036-8075, DOI: 10.1126/science.abb7498 * |
JANOWITZ TOBIAS, GABLENZ EVA, PATTINSON DAVID, WANG TIMOTHY C, CONIGLIARO JOSEPH, TRACEY KEVIN, TUVESON DAVID: "Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series", GUT MICROBIOTA, BRITISH MEDICAL ASSOCIATION , LONDON, UK, vol. 69, no. 9, 1 September 2020 (2020-09-01), UK , pages 1592 - 1597, XP055793948, ISSN: 0017-5749, DOI: 10.1136/gutjnl-2020-321852 * |
LOU YAN; LIU LIN; YAO HANGPING; HU XINGJIANG; SU JUNWEI; XU KAIJIN; LUO RUI; YANG XI; HE LINGJUAN; LU XIAOYANG; ZHAO QINGWEI; LIAN: "Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, ELSEVIER AMSTERDAM, NL, vol. 157, 25 October 2020 (2020-10-25), NL , XP086422279, ISSN: 0928-0987, DOI: 10.1016/j.ejps.2020.105631 * |
SAHA RUDRA P., SHARMA ASHISH RANJAN, SINGH MANOJ K., SAMANTA SAIKAT, BHAKTA SWARNAV, MANDAL SNEHASISH, BHATTACHARYA MANOJIT, LEE S: "Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19", FRONTIERS IN PHARMACOLOGY, FRONTIERS RESEARCH FOUNDATION, CH, vol. 11, 19 January 2020 (2020-01-19), CH , XP055873445, ISSN: 1663-9812, DOI: 10.3389/fphar.2020.01258 * |
Also Published As
Publication number | Publication date |
---|---|
WO2022053993A2 (en) | 2022-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2022053993A3 (en) | Treatments for sars-cov-2 infection (covid-19) | |
NO20052362L (en) | Methods of administering dalbavancin for the treatment of bacterial infections | |
WO2020132661A3 (en) | Inhibitors of fibroblast activation protein | |
WO2023122260A3 (en) | Inhibitors of sars-cov-2 | |
MX2022001004A (en) | Enzyme inhibitors. | |
EP4119156A4 (en) | Medicament for treatment and/or prevention of cancer | |
EP3865140A8 (en) | Preventive and/or therapeutic agent for clostridium difficile infection | |
EP4101449A4 (en) | Application of nitazoxanide and active form thereof, tizoxanide, in treatment of sars-cov-2 infection | |
MX2023004188A (en) | Phospholipid compounds and uses thereof. | |
WO2023081830A3 (en) | Compositions and treatments with nirogacestat | |
WO2021195470A3 (en) | Identification and use of compounds in the treatment or prevention of severe acute respiratory syndrome coronavirus 2 | |
WO2022020353A3 (en) | Methods and compositions for treatment and prevention of coronavirus infection | |
EP3782631A4 (en) | Agent for prevention and/or treatment of pseudomonas aeruginosa infection | |
WO2020086954A3 (en) | Treatments for charcot-marie-tooth disease | |
WO2020109233A3 (en) | Trmt2a inhibitors for use in the treatment of polyglutamine diseases | |
WO2023114867A3 (en) | Therapeutic targeting of gastrointestinal stromal tumor (gist) by disrupting the menin-mll epigenetic complex | |
GEP20227384B (en) | Topical formulations comprising strontium and methylsulfonylmethane (msm) and methods of treatment | |
MX2022016179A (en) | Compounds and methods for treating fungal infections. | |
MX2023009041A (en) | Use of proteasome inhibitors in the treatment of coronavirus infections. | |
WO2018140707A8 (en) | Synergistic combination of thermolysin and an antibacterial agent to reduce or eliminate bacterial biofilms from surfaces | |
EP4223303A4 (en) | Antiviral agent for preventing or treating covid-19 infection | |
EP4103179A4 (en) | Combination therapy for treating amyotrophic lateral using pridopidine and another active agent | |
EP4119159A4 (en) | Medicament for treatment and/or prevention of cancer | |
EP4119157A4 (en) | Medicament for treatment and/or prevention of cancer | |
EP4119160A4 (en) | Medicament for treatment and/or prevention of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21866190 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202347025930 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21866190 Country of ref document: EP Kind code of ref document: A2 |